This activity has expired. CME/CE credit is no longer available and the following content may not be up-to-date.
Start the program by clicking on the Start Program icon at the bottom of this page.
Program Title
Evaluating & Treating Newly Diagnosed Malignant Gliomas
Release Date: May-22-09
Credit Expiration Date: May-31-10
Program Developer/Facilitator
Medical Communications Media, Inc.
Target Audience
This educational activity is designed to meet the needs of neurosurgeons, neuro-oncologists, radiation oncologists, medical oncologists, and other healthcare providers interested in the treatment of primary gliomas.
Credit Hours
CME 0.75
Medium
e-Monograph
Program Description
When patients present with neurological or cognitive deficits that indicate a possible brain tumor, a number of crucial decisions must be made to generate an accurate diagnosis, effective treatment regimen, and hopeful prognosis. This 3-part educational activity outlines rigorous evaluation methods and treatment options for both the deadliest malignant glioma (glioblastoma) and the least lethal (oligodendroglioma). While many questions about how best to manage these tumors remain unresolved, innovative treatment approaches have brought a renewed sense of optimism for patients with newly diagnosed tumors.
Learning Objectives
Upon completion of this educational activity, the participant should be able to:
1.
Describe emerging concepts and treatments in the management of brain tumors.
2.
List 3 components that are important to an assessment of a patient with a newly diagnosed malignant brain tumor.
3.
Identify the new standard of care for glioblastoma.
4.
Compare therapeutic regimens for oligodendroglioma.
Faculty
Arnab Chakravarti, MD
Chair & Professor, Department of Radiation Oncology
Ohio State University Medical School
Co-Director, Brain Tumor Program
Arthur G. James Comprehensive Cancer Center and
Richard L. Solove Research Institute
Columbus, OH
Matthew G. Ewend, MD
Associate Professor of Neurosurgery
Chief, Division of Neurosurgery
University of North Carolina at Chapel Hill
Chapel Hill, NC
Andrew B. Lassman, MD
Assistant Professor of Neurology
Memorial Sloan-Kettering Cancer Center
New York, NY
Volker W. Stieber, MD
Assistant Professor
Department of Radiation Oncology
Wake Forest University
Winston-Salem, NC
Disclosures
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
Dr. Chakravarti
discloses that he serves on the speakers’ bureau of Schering-Plough and is a consultant for Genentech.
Dr. Ewend
discloses receipt of research support from Eisai Pharmaceuticals.
Dr. Lassman
discloses that he serves on the speakers’ bureau of Schering-Plough and is a consultant for Bristol-Myers Squibb, Cephalon, Eisai, Genentech, and Imclone. He has also received research support from AstraZeneca, Keryx, and Sigma Tau.
Dr. Stieber
discloses that he serves on advisory committees for Cytyc Corporation and Monteris Medical.
Commercial Support Statements
This activity is supported by an educational grant from Schering-Plough.
Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 0.75
AMA PRA Category 1 Credit
TM
. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Instructions
1.
Please turn off all pop-up blockers and click on the "Start Program" icon at the bottom of the page. If you have not previously registered with this website, you will be taken to the login/registration page where you will be able to register as a new GliomaEd.com member. If you have previously registered, you will be asked to verify or correct existing registration information. When ready, click on the "Start Program" icon.
2.
This program, post-test, and evaluation will take approximately 45 minutes to complete.
3.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 75% on the post-test is required for a CME certificate. One retake is permitted.
Certificate Fee
$0.00
Disclaimer
© 2009. All rights reserved. None of the contents of this publication may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication are those of the faculty members and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or Schering-Plough. Any medications, diagnostic procedures, or treatments discussed by the faculty members should not be used by clinicians or other healthcare professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.
Related Programs
Title
Audience
Medium
